ArticleSurgical case reports2026
Upfront Cytoreductive Surgery as a Bridge to Systemic Therapy for Recurrent Peritoneal Dissemination of Ovarian Angiosarcoma: A Pediatric Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOvarian angiosarcoma is exceptionally rare, especially considering those few pediatric cases that have been reported, and displays a poor outcome. Recurrent peritoneal dissemination of ovarian angiosarcoma is generally managed with systemic therapy, but refractory malignant ascites may compromise performance status and hinder treatment delivery. Herein, we report a pediatric case in which upfront cytoreductive surgery (CRS) controlled refractory ascites and enabled subsequent systemic therapy for recurrent peritoneal dissemination. CASE PRESENTATION: A 14-year-old girl presented with acute abdominal pain and underwent left salpingo-oophorectomy for a large ovarian tumor. Histopathological examination revealed mucinous carcinoma occupying most of the mass, with focal areas containing angiosarcoma and mature teratoma components. Staging surgery 1 month later showed no residual malignancy, and no adjuvant chemotherapy was administered. Six months after the initial surgery, she developed diffuse peritoneal dissemination and massive hemorrhagic ascites. Paracentesis provided only transient relief; ascites rapidly reaccumulated, oral intake became impossible, and progressive anemia required daily red blood cell transfusions for 6 consecutive days. Cell-block cytology of ascitic fluid suggested angiosarcoma. As adequate ascites control was not achievable and chemotherapy was considered impracticable, upfront CRS was performed, consisting of a total hysterectomy with right salpingo-oophorectomy and debulking of peritoneal dissemination. Resected lesions were exclusively composed of angiosarcoma. Postoperatively, the ascites markedly decreased, enabling the initiation of chemotherapy on POD 7 and completion of adjuvant chemoradiotherapy without substantial interruption. The patient has remained free of radiologic disease and ascites for 1 year after the initial surgery.
conclusionsThis report demonstrated that CRS could provide effective control of malignant hemorrhagic ascites in recurrent peritoneal dissemination of ovarian angiosarcoma. Upfront CRS can be considered as a potential initial treatment option, facilitating the timely delivery and completion of subsequent systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.